Abstract
Introduction and objectives: The Glutamic acid decarboxylase 65 (GAD-65) autoantibody and anti-insulin autoantibody (IAA) are serum markers of autoimmune diabetic patients. The presence of these autoantibodies in aging diabetic patients can differenciate the latent autoimmune diabetes in adults (LADA) from type 2 diabetes. Patients with these auto-antibodies were considered high risk group and will progress into insulin dependent in 5-7 years. This study was carried out with aims:(1) To define the positive rate, the concentration of GAD-65 autoantibody and IAA on lean patients with diabetes. (2) To survey the correlation between the presence of GAD-65 autoantibody, IAA and several clinical and laboratory characteristics of these patients. Objects and methods: 86 patients diagnosed of diabetes following the ADA 2015 criteria, fasting glucose ≥ 126 mg/dL (or ≥ 7.0 mmol/L) and HbA1C > 6.5%. Indirect ELISA technique was performed to measure anti GAD-65 autoantibody and IAA. Kits used in the study were AESKULISA GAD-65 from AESKU Company- Germany and IAA ELISA from DRG Company- Germany. Results: the positive rate with anti GAD-65 and IAA was 48.84% and 30.23% respectively. The positive rate with one of the two antibodies was 55.81%; the positive rate with both antibodies was 23.26%. Mean concentration of GAD-65 positive was 51.08 ± 16,86 IU/mL; The average concentration of IAA positive was 1,46 ± 0,27 U/mL. Regarding the correlation between the concentration of GAD-65, IAA and laboratory data: there is a statistically significant difference (p<0.05) between positive GAD-65 antibody and insulin concentration. A statistically significant difference between GAD-65 antibody and hypertriclyceridemia in the studied and control group (p<0.05) is also observed. Keywords: glutamic acid decarboxylase (GAD) autoantibody, insulin autoantibody, diabetes mellitus
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call